CelLBxHealth PLC

DWV

Company Profile

  • Business description

    CelLBxHealth PLC is engaged in the development and commercialisation of the Parsortix platform, with deployment in liquid biopsy - non-invasive cancer diagnostics. It operates in single segment of commercialisation of its Parsortix cell separation platform. It generates revenue from contracts with customers in the research-use market, with customers located across multiple geographic regions. Geographically it operates in UK, Europe, North America, and Rest of World with majority of revenue deriving from Europe and North America.

  • Contact

    10 Nugent Road
    The Surrey Research Park
    Surrey
    GuildfordGU2 7AF
    GBR

    T: +44 1483343434

    E: [email protected]

    https://www.cellbxhealth.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    114

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,147.33949.73-1.93%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,617.731,261.47-5.28%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,910.39265.44-3.70%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers